Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan

Journal of Infection

Volumn 61, Issue 5, 2010, Pages 410-418

  Kohno, Shigeru ^a   Izumikawa, Koichi ^a   Ogawa, Kenji ^b   Kurashima, Atsuyuki ^c   Okimoto, Niro ^d   Amitani, Ryoichi ^e   Kakeya, Hiroshi ^a   Niki, Yoshihito ^f   Miyazaki, Yoshitsugu ^g  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Meito ku   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e OSAKA RED CROSS HOSPITAL   (Japan)

^f SHOWA UNIVERSITY   (Japan)

^g NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Chronic pulmonary aspergillosis; Micafungin; Voriconazole

Indexed keywords

MICAFUNGIN; VORICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLUS; BLOOD PRESSURE; CHRONIC PULMONARY ASPERGILLOSIS; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FEMALE; FUNGUS CULTURE; HALLUCINATION; HEART VENTRICLE EXTRASYSTOLE; HEMOPTYSIS; HUMAN; HYPERKALEMIA; JAPAN; LABORATORY TEST; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; OPEN STUDY; OUTCOME ASSESSMENT; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SKIN DISCOLORATION; THORAX RADIOGRAPHY; TREATMENT DURATION; VISUAL DISORDER; VOMITING;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ASPERGILLUS; CHRONIC DISEASE; ECHINOCANDINS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PULMONARY ASPERGILLOSIS; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 78149360137     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.08.005     Document Type: Article

References (23)

1. Denning D.W. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001, 7(Suppl. 2):25-31.
2. Hope W.W., Walsh T.J., Denning D.W. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005, 43(Suppl. 1):S207-S238.
3. Gefter W.B., Weingrad T.R., Epstein D.M., Ochs R.H., Miller W.T. " Semi-invasive" pulmonary aspergillosis: a new look at the spectrum of aspergillus infections of the lung. Radiology 1981, 140:313-321.
4. Binder R.E., Faling L.J., Pugatch R.D., Mahasaen C., Snider G.L. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982, 61:109-124.
5. Denning D.W., Riniotis K., Dobrashian R., Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003, 37(Suppl. 3):S265-S280.
6. Hope W.W., Kruhlak M.J., Lyman C.A., Petraitiene R., Petraitis V., Francesconi A., et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 2007, 195:455-466.
7. Saraceno J.L., Phelps D.T., Ferro T.J., Futerfas R., Schwartz D.B. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997, 112:541-548.
8. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004, 36:372-379.
9. Izumikawa K., Ohtsu Y., Kawabata M., Takaya H., Miyamoto A., Sakamoto S., et al. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007, 45:273-278.
10. Camuset J., Nunes H., Dombret M.C., Bergeron A., Henno P., Philippe B., et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007, 131:1435-1441.
11. Sambatakou H., Dupont B., Lode H., Denning D.W. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006, 119(527). e17-24.
12. Jain L.R., Denning D.W. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect 2006, 52:e133-e137.
13. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Infectious diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
14. Tomishima M., Ohki H., Yamada A., Takasugi H., Maki K., Tawara S., et al. FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo) 1999, 52:674-676.
15. Tawara S., Ikeda F., Maki K., Morishita Y., Otomo K., Teratani N., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000, 44:57-62.
16. Ikeda F., Wakai Y., Matsumoto S., Maki K., Watabe E., Tawara S., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000, 44:614-618.
17. Matsumoto S., Wakai Y., Nakai T., Hatano K., Ushitani T., Ikeda F., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 2000, 44:619-621.
18. Espinel-Ingroff A., Johnson E., Hockey H., Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole. Phase III clinical studies. J Antimicrob Chemother 2008, 61:616-620.
19. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001, 39:954-958.
20. Program CTE Common toxicity criteria manual 2003, Version 3.0, National Cancer Institute, Bethesda, MD.
21. Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630-637.
22. Kimura M., Ieiri I., Mamiya K., Urae A., Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998, 20:243-247.
23. Smith N.L., Denning D.W. Underlying conditions in chronic pulmonary aspergillosis, including simple aspergilloma. Eur Respir J 2010, [Epub ahead of print].